Tetanus Wound Prophylaxis Pathway

The wound, the immunisation history, and the choice between Td, Tdap and TIG · v1.4

  • Classify the wound, then enter the vaccination history.
  • Treat an unknown or uncertain history as zero doses.
  • The immune status and the age group default to an immunocompetent adult and can be changed.
  • You get whether tetanus toxoid, tetanus immunoglobulin, both or neither are due, and the wound care that goes with it.
  • History is read against the Indian schedule, in which Td replaced TT in 2018-19.

  • The treatment of established tetanus, which is an intensive care problem rather than a prophylaxis decision.
  • Routine immunisation of somebody who has not been injured. The childhood schedule sits in the immunisation pathway.
  • Rabies post-exposure prophylaxis, which an animal bite needs alongside this and which is decided in its own pathway.
Wound Classification
Evidence-Based Pearls

1. The Prophylaxis Table

The rule that governs the table: an unknown or uncertain vaccination history counts as zero previous doses. Surviving tetanus confers no immunity either: a patient who has recovered from clinical tetanus still needs the full vaccination course.
Vaccination History Clean, Minor Wound Tetanus-Prone Wound
Unknown or <3 doses Td/Tdap: YES
TIG: No
Td/Tdap: YES
TIG: YES (250 IU)
≥3 doses, booster <5 yrs Td/Tdap: No
TIG: No
Td/Tdap: No
TIG: No
≥3 doses, booster 5-10 yrs Td/Tdap: No
TIG: No
Td/Tdap: YES
TIG: No
≥3 doses, booster >10 yrs Td/Tdap: YES
TIG: No
Td/Tdap: YES
TIG: No*
*The exception for immunocompromised patients: where there is HIV/AIDS or severe immunodeficiency and the wound is contaminated, give TIG regardless of what the vaccination history says. The history is a poor guide to protection when the immune response to toxoid may never have been made.

2. Wound Classification: Clean vs Tetanus-Prone

Feature Clean, Minor Tetanus-Prone
Age of wound <6 hours >6 hours
Configuration Linear, sharp edge Stellate, avulsion, crush, missile
Depth <1 cm >1 cm (deep)
Mechanism Sharp object (knife, glass) Puncture, crush, burn, frostbite
Contamination None / minimal Soil, faeces, saliva, dirt, rust
Tissue viability Viable, well-perfused Devitalised, ischaemic, necrotic
Infection Absent Signs of infection present
Pearl: If ANY single feature from the tetanus-prone column is present, classify the wound as tetanus-prone. When in doubt, treat as tetanus-prone.

3. Which Vaccine? Td vs Tdap vs DTaP

Patient Age Preferred Vaccine Alternative
<7 years DTaP (or DTwP in NIS context) DT if pertussis contraindicated
7-18 years Tdap (if never received Tdap) Td if Tdap previously received or unavailable
≥19 years Tdap (if never received Tdap) Td if Tdap previously received
Pregnant Tdap 27-36 weeks (each pregnancy) Td if Tdap unavailable
  • Key Difference: Lowercase letters (d, p) denote reduced antigen content in adult formulations. Paediatric DTaP has 3-4 times more diphtheria toxoid than adult Td.
  • Tdap Priority: Every adult should receive at least 1 lifetime dose of Tdap. If Tdap status is unknown, use Tdap for wound management rather than Td.
  • Indian Context: Td replaced TT in the NIS (2018-19). In government settings, Td is the standard. Tdap availability is primarily in private practice.

4. Tetanus Immunoglobulin (TIG): The Details

Parameter Detail
Product Human TIG (preferred). Equine ATS if human TIG unavailable (higher anaphylaxis risk; requires sensitivity testing).
Dose 250 IU IM for wounds of average severity. 500 IU if wound >24 hours old or heavily contaminated.
Administration IM injection. When given with Td/Tdap, use separate syringes at different anatomical sites.
Mechanism Provides immediate passive immunity by neutralising circulating tetanus toxin. Cannot reverse toxin already bound to nerve endings.
Duration Passive protection only. Patient still requires active immunisation (Td/Tdap) for long-term immunity.

5. Wound Management: The Surgical Essentials

Practice advisory: vaccine and TIG do not stand in for wound care. Clean the wound thoroughly and debride devitalised tissue, whatever prophylaxis has been given.
  • Debridement: Excise devitalised, necrotic, and ischaemic tissue. C. tetani thrives in anaerobic, devitalised tissue.
  • Closure: Tetanus-prone wounds should generally be left open or closed by delayed primary closure to avoid creating anaerobic conditions.
  • Antibiotics: Routine antibiotic prophylaxis is NOT indicated solely for tetanus prevention. However, contaminated wounds may warrant antibiotics for polymicrobial infection risk (Metronidazole or Penicillin if clinical tetanus is suspected).

6. Cautions in the Emergency Department

What the surveillance shows: in a California study covering 2008-2014, of the tetanus patients who had presented for care after the injury, only 22% were given appropriate prophylaxis at that visit. Case fatality is still 13-18% with full intensive care.
  • Caution: Assuming "rusty nail" is the only mechanism. Tetanus-prone wounds include garden injuries, animal bites, burns, compound fractures, and even surgical wounds.
  • Caution: Not completing the primary series. If <3 doses have been received, the patient needs a full primary series: dose 2 at ≥4 weeks, dose 3 at 6-12 months after dose 2.
  • Pearl: Do not restart a vaccine series if doses are delayed. Continue from where the patient left off.
  • Pearl: ~25% of tetanus cases have no identifiable wound or portal of entry. Ensure routine 10-year boosters are up to date.

7. Tetanus in India: Context

  • Maternal & Neonatal Tetanus: India was certified for elimination of MNT by WHO in July 2016. However, neonatal tetanus cases continue to be reported (409 cases per HMIS 2021-22).
  • Adult Tetanus: Cases are primarily in unvaccinated or partially vaccinated elderly agricultural workers. Td vaccine is now given at 10 and 16 years and to pregnant women under NIS.
  • Diphtheria Resurgence: The shift from TT to Td in 2018-19 was driven by rising diphtheria cases in older age groups with waning immunity. Td provides dual protection.
  • Equine ATS Availability: Where human TIG cannot be had, equine ATS (1,500-3,000 IU IM after a sensitivity test) may be used. Human TIG is strongly preferred, because serum sickness follows the equine product far more often.

8. Special Populations

Population Key Consideration
Pregnant Women Td/Tdap is safe. Tdap is preferred at 27-36 weeks (each pregnancy) for passive neonatal pertussis protection. Category C vaccine.
HIV/AIDS Give TIG for ALL contaminated wounds regardless of vaccination history. Immune response to toxoid may be impaired.
Elderly (≥65 yrs) Incidence is twice that in younger adults. Immunosenescence, outdoor and agricultural work, and boosters nobody offered all contribute. Check that the 10-year booster is up to date.
Infants <6 weeks No tetanus toxoid vaccine is licensed. Give TIG only for contaminated wounds.
Arthus reaction history Do not give Td/Tdap booster more frequently than every 10 years. For wound management, give TIG alone if within 10 years of last dose.

9. What This Tool Does Not Print

  • A sensitivity test method for equine ATS. Section 7 says to use one and gives none.
  • A serological test for immunity. The decision runs on the vaccination history and the wound alone.
  • An antibiotic regimen for the wound itself. Section 5 gives the tetanus position and nothing wider.
Abbreviations ACIP (Advisory Committee on Immunization Practices) · AIDS (Acquired Immunodeficiency Syndrome) · ATS (Anti-Tetanus Serum, equine) · CDC (Centers for Disease Control and Prevention) · C. tetani (Clostridium tetani) · DT (Diphtheria and Tetanus, paediatric) · DTaP (Diphtheria, Tetanus and acellular Pertussis) · DTwP (Diphtheria, Tetanus and whole-cell Pertussis) · HIV (Human Immunodeficiency Virus) · HMIS (Health Management Information System) · IM (Intramuscular) · IU (International Units) · MNT (Maternal and Neonatal Tetanus) · MSD (Merck Sharp & Dohme) · NIS (National Immunization Schedule) · Td (Tetanus and adult Diphtheria) · Tdap (Tetanus, Diphtheria and acellular Pertussis) · TIG (Tetanus Immunoglobulin, human) · TT (Tetanus Toxoid) · WHO (World Health Organization)
References
  1. Centers for Disease Control and Prevention (CDC). Clinical Guidance for Wound Management to Prevent Tetanus. CDC; Updated June 2025.
  2. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the ACIP. MMWR Recomm Rep. 2018;67(No. RR-2):1-44.
  3. World Health Organization. Tetanus vaccines: WHO position paper, February 2017. Wkly Epidemiol Rec. 2017;92(6):53-76.
  4. Ministry of Health and Family Welfare, Government of India. Tetanus and Adult Diphtheria (Td) Operational Guidelines. NHM; 2019.
  5. American Academy of Pediatrics. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. 33rd ed. Itasca, IL: AAP; 2024.
  6. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet. 2007;370(9603):1947-1959.
  7. California Department of Public Health. Tetanus Quicksheet. CDPH; February 2025.
  8. Hassel B. Tetanus: Pathophysiology, Treatment, and the Possibility of Using Botulinum Toxin against Tetanus-Induced Rigidity and Spasms. Toxins. 2013;5(1):73-83.
How to Cite This Tool

DOIhttps://doi.org/10.5281/zenodo.22401651

AMA Style:Umakanth S. Tetanus Wound Prophylaxis Pathway. Version 1.4. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/tetanus-wound-prophylaxis. doi:10.5281/zenodo.22401651

Vancouver Style:Umakanth S. Tetanus Wound Prophylaxis Pathway [Internet]. Version 1.4. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/tetanus-wound-prophylaxis. doi:10.5281/zenodo.22401651

Category Immunisation & ProphylaxisPathway
Specialties Internal Medicine, Infectious Diseases

Written and maintained by

Dr Shashikiran Umakanth

Last revised 24 August 2026

How these tools are written and reviewed